177 related articles for article (PubMed ID: 22307631)
1. Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity.
Goh AM; Lim CY; Chiam PC; Li L; Mann MB; Mann KM; Menendez S; Lane DP
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1685-90. PubMed ID: 22307631
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.
Gottlieb E; Haffner R; King A; Asher G; Gruss P; Lonai P; Oren M
EMBO J; 1997 Mar; 16(6):1381-90. PubMed ID: 9135153
[TBL] [Abstract][Full Text] [Related]
3. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of taurine transporter gene (TauT) by p53 in renal cells.
Han X; Patters AB; Chesney RW
J Biol Chem; 2002 Oct; 277(42):39266-73. PubMed ID: 12163498
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo.
Ohtani S; Kagawa S; Tango Y; Umeoka T; Tokunaga N; Tsunemitsu Y; Roth JA; Taya Y; Tanaka N; Fujiwara T
Mol Cancer Ther; 2004 Jan; 3(1):93-100. PubMed ID: 14749479
[TBL] [Abstract][Full Text] [Related]
7. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism.
Liedtke C; Groger N; Manns MP; Trautwein C
J Biol Chem; 2003 Jul; 278(30):27593-604. PubMed ID: 12748179
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific p53 expression in the nervous system.
Tendler Y; Weisinger G; Coleman R; Diamond E; Lischinsky S; Kerner H; Rotter V; Zinder O
Brain Res Mol Brain Res; 1999 Sep; 72(1):40-6. PubMed ID: 10521597
[TBL] [Abstract][Full Text] [Related]
9. PML is a direct p53 target that modulates p53 effector functions.
de Stanchina E; Querido E; Narita M; Davuluri RV; Pandolfi PP; Ferbeyre G; Lowe SW
Mol Cell; 2004 Feb; 13(4):523-35. PubMed ID: 14992722
[TBL] [Abstract][Full Text] [Related]
10. The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1.
Fortin A; MacLaurin JG; Arbour N; Cregan SP; Kushwaha N; Callaghan SM; Park DS; Albert PR; Slack RS
J Biol Chem; 2004 Jul; 279(27):28706-14. PubMed ID: 15105421
[TBL] [Abstract][Full Text] [Related]
11. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
Valente LJ; Gray DH; Michalak EM; Pinon-Hofbauer J; Egle A; Scott CL; Janic A; Strasser A
Cell Rep; 2013 May; 3(5):1339-45. PubMed ID: 23665218
[TBL] [Abstract][Full Text] [Related]
12. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.
Ciribilli Y; Singh P; Spanel R; Inga A; Borlak J
Oncotarget; 2015 Oct; 6(31):31569-92. PubMed ID: 26427040
[TBL] [Abstract][Full Text] [Related]
13. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.
Fen CX; Coomber DW; Lane DP; Ghadessy FJ
J Mol Biol; 2007 Aug; 371(5):1238-48. PubMed ID: 17610896
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway.
Zhang G; Chen F; Cao Y; See WA
Urol Oncol; 2007; 25(3):221-7. PubMed ID: 17483019
[TBL] [Abstract][Full Text] [Related]
15. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
16. Direct repression of the Mcl-1 promoter by E2F1.
Croxton R; Ma Y; Song L; Haura EB; Cress WD
Oncogene; 2002 Feb; 21(9):1359-69. PubMed ID: 11857079
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha induced p21(WAF1) but not Bax in colon cancer cells WiDr with mutated p53: important role of protein stabilization.
Kobayashi N; Takada Y; Hachiya M; Ando K; Nakajima N; Akashi M
Cytokine; 2000 Dec; 12(12):1745-54. PubMed ID: 11097743
[TBL] [Abstract][Full Text] [Related]
18. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.
Komarova EA; Chernov MV; Franks R; Wang K; Armin G; Zelnick CR; Chin DM; Bacus SS; Stark GR; Gudkov AV
EMBO J; 1997 Mar; 16(6):1391-400. PubMed ID: 9135154
[TBL] [Abstract][Full Text] [Related]
19. The critical role of the PE21 element in oncostatin M-mediated transcriptional repression of the p53 tumor suppressor gene in breast cancer cells.
Li C; Ahlborn TE; Tokita K; Boxer LM; Noda A; Liu J
Oncogene; 2001 Dec; 20(57):8193-202. PubMed ID: 11781835
[TBL] [Abstract][Full Text] [Related]
20. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
